XML 67 R46.htm IDEA: XBRL DOCUMENT
v3.25.1

Collaborative Research, Development, and License Agreements - Additional Information (Details) - USD ($) |  |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Dec. 05, 2022 | Feb. 22, 2022 | Mar. 31, 2025 | May 31, 2011 | Mar. 31, 2009 | Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Total Revenues |  |  |  |  |  | $ 144,000 | $ 109,000 |
Licensing Agreements [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Amortization expense of licenses |  |  |  |  |  | $ 3,000 | 5,000 |
Weighted average remaining amortization period for all licenses |  |  |  |  |  | 2 years |  |
Annual amortization expense of licenses year 1 |  |  | $ 2,000 |  |  | $ 2,000 |  |
Annual amortization expense of licenses year 2 |  |  | 2,000 |  |  | 2,000 |  |
Annual amortization expense of licenses year 3 |  |  | 2,000 |  |  | 2,000 |  |
BICO Group AB [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Nonrefundable upfront fee paid |  | $ 1,500,000 |  |  |  |  |  |
BICO Group AB [Member] | Sales Based Royalties [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Total Revenues |  |  |  |  |  | 119,000 | 109,000 |
University of Missouri [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalty fees percentage minimum |  |  |  |  | 1.00% |  |  |
Royalty fees percentage maximum |  |  |  |  | 3.00% |  |  |
Upfront payment | $ 50,000,000 |  |  |  |  |  |  |
Clemson University [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Minimum annual royalty paid |  |  |  |  |  | 40,000 | $ 40,000 |
Upfront payment |  |  |  |  |  | $ 0 |  |
Minimum annual royalty payment due |  |  |  |  |  |  |  | $ 40,000
Clemson University [Member] | Sublicense Agreements [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of royalty revenue from sublicensee |  |  |  |  |  | 40.00% |  |
Clemson University [Member] | Licensing Agreements [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalty fees percentage minimum |  |  |  | 1.50% |  |  |  |
Royalty fees percentage maximum |  |  |  | 3.00% |  |  |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalty fees percentage minimum |  |  |  |  |  | 1.00% |  |
Royalty fees percentage maximum |  |  |  |  |  | 1.125% |  |
Amount paid at the closing of the sale |  |  | $ 100,000 |  |  |  |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] | 45 days of Dosing of First Patient in a Phase III Clinical Trial [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 500,000 |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] | 45 days of FDA Approval of First Licensed Product [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | 1,000,000 |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] | 45 Days of First Commercial Sale of Licensed Product in Territory [Member] |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 1,500,000 |  |

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount paid at the closing of the sale. + References No definition available. + Details
Name: | vivs_AmountPaidAtTheClosingOfTheSale
Namespace Prefix: | vivs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | vivs_MilestonePayments
Namespace Prefix: | vivs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum annual royalty payment. + References No definition available. + Details
Name: | vivs_MinimumAnnualRoyaltyPayment
Namespace Prefix: | vivs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable upfront fee paid. + References No definition available. + Details
Name: | vivs_NonrefundableUpfrontFeePaid
Namespace Prefix: | vivs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of royalty revenue from sublicensee. + References No definition available. + Details
Name: | vivs_PercentageOfRoyaltyRevenueFromSublicensee
Namespace Prefix: | vivs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty fees percentage maximum. + References No definition available. + Details
Name: | vivs_RoyaltyFeesPercentageMaximum
Namespace Prefix: | vivs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty fees percentage minimum. + References No definition available. + Details
Name: | vivs_RoyaltyFeesPercentageMinimum
Namespace Prefix: | vivs_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty payments under license agreement due year two. + References No definition available. + Details
Name: | vivs_RoyaltyPaymentsUnderLicenseAgreementDueYearTwo
Namespace Prefix: | vivs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront fee payment. + References No definition available. + Details
Name: | vivs_UpfrontFeePayment
Namespace Prefix: | vivs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vivs_BICOGroupABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vivs_SalesBasedRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vivs_UniversityOfMissouriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vivs_ClemsonUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vivs_SublicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vivs_SalkInstituteForBiologicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vivs_DaysOfTheDosingOfTheFirstPatientInAPhaseIiiClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vivs_DaysOfFdaApprovalOfFirstLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vivs_DaysOfFirstCommercialSaleOfALicensedProductInTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |